CAPR News and Press, Capricor Therapeutics Inc. From 01/25/22

Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment* of Duchenne Muscular Dystrophy in US PR Newswire KYOTO, Japan , Jan. 25, 2022 /PRNewswire/ -- *NS Pharma Note: CA...

In this article, we take a closer look at 5 penny stocks gaining ground after releasing big news today. Thanks to even more stock market uncertainty, retail traders have turned attention to daily trends, and rightfully so. The last week has seen markets pop and drop significant percentages ...

-Partnership Leverages Nippon Shinyaku’s Deep Experience in Drug Development for Rare Diseases and its Commercial DMD Franchise in the U.S.- -Capricor to Receive an Upfront Payment of $30 Million, Additional Potential Milestone Payments of up to $705 Million- ...

Capricor Therapeutics (CAPR) announces new updates on its vaccine and therapeutic development programs focused on COVID-19. The preclinical data describes the potential for Capricor’s multivalent exosome mRNA vaccine candidate for SARS-CoV-2 to generate a strong T-cell response against...

Capricor’s Exosome-based mRNA Vaccine for SARS-CoV-2 -In-Vivo Preclinical Data Published in the Journal of Biological Chemistry - -Preclinical Data Demonstrates Strong T-Cell Response for High Conserved N Protein which may Confer Longer Lasting Immunity-...

SAN DIEGO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) (“Capricor” or “the Company”), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a bro...

Capricor Therapeutics, Inc. (CAPR) Q3 2021 Earnings Conference Call November 10, 2021 4:30 PM ET Company Participants AJ Bergmann - Chief Financial Officer Linda Marbán - Chief Executive Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Presentation Operator Greetings,...

Capricor Therapeutics (NASDAQ:CAPR): Q3 GAAP EPS of -$0.17 beats by $0.06. cash and cash equivalents balance totaled approximately $40.8M Press Release For further details see: Capricor Therapeutics EPS beats by $0.06

CAP-1002 – Capricor’s Cell Therapy Program for Duchenne Muscular Dystrophy -Phase 3 Pivotal Study Cleared to Proceed- -Presented Positive Phase 2 HOPE-2 Data at Late-Breaking Oral Presentation at the World Muscle Society Annual Meeting- -Met Primary...

LOS ANGELES, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial resul...